Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Anbal-cel: a novel anti-CD19 CAR-T therapy with dual silencing of PD-1 & TIGIT for LBCL

Won-Seog Kim • 11 Jun 2022
EHA 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Anbalcabtagene autoleucel CAR-T

Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, discusses a Phase I/II study evaluating anbalcabtagene autoleucel (anbal-cel), a novel anti-CD19 CAR-T cell therapy, in large B-cell lymphoma (LBCL). Prof. Kim briefly explains the mechanism of action of anbal-cel and the promise of this novel agent for the treatment of relapsed/refractory (R/R) disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Won-Seog Kim

1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
1:35
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
Won-Seog Kim • 16 Jun 2023
1:07
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
Won-Seog Kim • 16 Jun 2023
1:09
Interim analysis of anbal-cel for R/R DLBCL
Won-Seog Kim • 16 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals